AI-generated research brief — verify at source
Triplet KRd Maintenance Nearly Doubles Progression-Free Survival Over Lenalidomide Alone Post-Transplant
In a randomised phase 3 trial, carfilzomib-lenalidomide-dexamethasone (KRd) reduced the risk of disease progression or death by approximately 54% compared with lenalidomide monotherapy in newly diagnosed multiple myeloma patients following autologous stem-cell transplantation (median PFS 72.8 months vs 37.3 months; HR 0.46, 95% CI 0.30–0.70; p=0.0002). The magnitude of this benefit — nearly doubling median progression-free survival — supports a meaningful advantage for intensified triplet maintenance in this setting.
What Was Studied
The ATLAS trial examined whether replacing standard lenalidomide maintenance monotherapy with a three-drug regimen of carfilzomib, lenalidomide, and dexamethasone could meaningfully extend progression-free survival in patients with newly diagnosed multiple myeloma who had achieved at least stable disease following autologous haematopoietic stem-cell transplantation. The trial also incorporated a framework of MRD-guided de-escalation, testing whether personalised therapy adjustment based on disease response could be integrated into an intensified maintenance strategy.
How It Was Studied
ATLAS was an investigator-initiated, multicentre, open-label, phase 3 randomised superiority trial conducted at 12 academic and clinical centres across the United States and Poland. Adults aged 18 years or older with newly diagnosed multiple myeloma, at least stable disease after autologous HSCT, and an ECOG performance status of 0 or 1 were eligible. A total of 180 patients were enrolled and randomly assigned 1:1 to receive either KRd (n=92) or lenalidomide alone (n=88), with randomisation performed using permuted blocks via a web-based system. The median follow-up at the time of primary analysis was 69 months (IQR 57–77), providing a substantial window for evaluating durable disease control.
What Was Observed
- Progression-free survival was substantially longer in the KRd group. The 4-year PFS rate was 67.5% (95% CI 56.2–76.4) with KRd versus 38.0% (95% CI 27.6–48.2) with lenalidomide alone — a difference of nearly 30 percentage points. Median PFS reached 72.8 months in the KRd arm compared with 37.3 months in the lenalidomide arm, representing approximately 54% lower risk of progression or death (HR 0.46, 95% CI 0.30–0.70; log-rank p=0.0002).
- Grade 3–4 neutropenia was somewhat less frequent with KRd than with lenalidomide alone. Severe neutropenia occurred in 48% of KRd patients (44 of 91) versus 59% of lenalidomide patients (51 of 87), suggesting the triplet regimen did not meaningfully worsen this common haematological toxicity relative to monotherapy.
- Serious adverse events and treatment-related deaths occurred in both arms. Serious adverse events were reported in 30% of the KRd group and 23% of the lenalidomide group. Two deaths in each arm were considered possibly treatment-related: lung infections in the KRd group, and COVID-19 and heart failure in the lenalidomide group.
Why This Matters
Lenalidomide maintenance has long been the standard of care after autologous HSCT in multiple myeloma, and multidrug regimens have been considered an emerging but unvalidated alternative. This trial provides phase 3 randomised evidence that intensified triplet maintenance can substantially extend the period of disease control beyond what lenalidomide alone achieves. The trial’s integration of an MRD-guided de-escalation framework also demonstrates a potential pathway for tailoring treatment intensity to individual patient response, which could inform future personalised post-transplant strategies.
How to Read This Result
While the efficacy signal is compelling, the open-label design introduces the possibility of performance and assessment bias, the sample size of 180 is modest for a phase 3 trial, and overall survival data are not yet fully reported — all of which temper the certainty of these conclusions pending confirmatory evidence.
Limitations
The open-label design may have introduced bias in outcome assessment and patient management decisions. The enrolled population was 93% White, substantially limiting the generalisability of findings to more diverse patient groups. At 180 patients total, the trial is relatively small for a phase 3 study, reducing statistical power for subgroup analyses and secondary endpoints. Enrollment was confined to 12 centres in the USA and Poland, which may restrict applicability to healthcare settings with different patient profiles or treatment practices.